ENTA Key Statistics, Chart & Performance
The current stock price of ENTA is 14.73 USD. In the past month the price increased by 25.68%. In the past year, price increased by 144.28%.
ENTA Latest News, Press Relases and Analysis
ENTA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.63 | 394.69B | ||
| AMGN | AMGEN INC | 14.53 | 171.10B | ||
| GILD | GILEAD SCIENCES INC | 14.7 | 149.38B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.04 | 114.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.47 | 77.91B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 779.51 | 52.52B | ||
| INSM | INSMED INC | N/A | 42.02B | ||
| NTRA | NATERA INC | N/A | 32.01B | ||
| BIIB | BIOGEN INC | 10.4 | 25.54B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.72 | 21.27B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.26B | ||
| INCY | INCYTE CORP | 14.86 | 18.73B |
Related stock screener links
About ENTA
Company Profile
Enanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. The company is headquartered in Watertown, Massachusetts and currently employs 131 full-time employees. The company went IPO on 2013-03-21. The firm is engaged in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. The Company’s clinical programs are focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, including receptor tyrosine kinase (KIT) and STAT6 inhibition. The firm has two clinical-stage product candidates for RSV, which are zelicapavir and EDP-323. Glecaprevir, a protease inhibitor discovered by the Company, is part of one of the treatment regimens for curing chronic hepatitis c virus (HCV) infection and is sold by AbbVie in various countries under the tradenames MAVYRET (U.S.) and MAVIRET (ex-U.S.) (glecaprevir/pibrentasvir). The firm also has development programs in virology for SARS-CoV-2 and Hepatitis B virus.
Company Info
ENANTA PHARMACEUTICALS INC
4 Kingsbury Avenue
Watertown MASSACHUSETTS 02472 US
CEO: Jay R. Luly
Employees: 131
Phone: 16176070800
ENANTA PHARMACEUTICALS INC / ENTA FAQ
What does ENTA do?
Enanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. The company is headquartered in Watertown, Massachusetts and currently employs 131 full-time employees. The company went IPO on 2013-03-21. The firm is engaged in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. The Company’s clinical programs are focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, including receptor tyrosine kinase (KIT) and STAT6 inhibition. The firm has two clinical-stage product candidates for RSV, which are zelicapavir and EDP-323. Glecaprevir, a protease inhibitor discovered by the Company, is part of one of the treatment regimens for curing chronic hepatitis c virus (HCV) infection and is sold by AbbVie in various countries under the tradenames MAVYRET (U.S.) and MAVIRET (ex-U.S.) (glecaprevir/pibrentasvir). The firm also has development programs in virology for SARS-CoV-2 and Hepatitis B virus.
What is the current price of ENTA stock?
The current stock price of ENTA is 14.73 USD. The price increased by 4.17% in the last trading session.
What is the dividend status of ENANTA PHARMACEUTICALS INC?
ENTA does not pay a dividend.
How is the ChartMill rating for ENANTA PHARMACEUTICALS INC?
ENTA has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the GICS sector and industry of ENTA stock?
ENANTA PHARMACEUTICALS INC (ENTA) operates in the Health Care sector and the Biotechnology industry.
How is the valuation of ENANTA PHARMACEUTICALS INC (ENTA) based on its PE ratio?
ENANTA PHARMACEUTICALS INC (ENTA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.83).
ENTA Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to ENTA. When comparing the yearly performance of all stocks, ENTA is one of the better performing stocks in the market, outperforming 97.4% of all stocks.
ENTA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ENTA. ENTA has a bad profitability rating. Also its financial health evaluation is rather negative.
ENTA Financial Highlights
Over the last trailing twelve months ENTA reported a non-GAAP Earnings per Share(EPS) of -3.83. The EPS increased by 30.11% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -29.17% | ||
| ROE | -126.53% | ||
| Debt/Equity | 0.02 |
ENTA Forecast & Estimates
14 analysts have analysed ENTA and the average price target is 19.38 USD. This implies a price increase of 31.57% is expected in the next year compared to the current price of 14.73.
For the next year, analysts expect an EPS growth of 19.02% and a revenue growth -2.24% for ENTA